Cargando…

Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial

BACKGROUND: BNT162b2 by Pfizer-BioNTech and mRNA-1273 by Moderna are the most commonly used vaccines to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Head-to-head comparison of the efficacy of these vaccines in immunocompromised patients is lacking. METHODS: Parall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Speich, Benjamin, Chammartin, Frédérique, Abela, Irene A, Amico, Patrizia, Stoeckle, Marcel P, Eichenberger, Anna L, Hasse, Barbara, Braun, Dominique L, Schuurmans, Macé M, Müller, Thomas F, Tamm, Michael, Audigé, Annette, Mueller, Nicolas J, Rauch, Andri, Günthard, Huldrych F, Koller, Michael T, Trkola, Alexandra, Briel, Matthias, Kusejko, Katharina, Bucher, Heiner C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903480/ https://www.ncbi.nlm.nih.gov/pubmed/35234868 http://dx.doi.org/10.1093/cid/ciac169

Ejemplares similares

Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)
por: Griessbach, Alexandra, et al.
Publicado: (2023)

A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®
por: Speich, Benjamin, et al.
Publicado: (2021)

Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2)
por: Griessbach, Alexandra, et al.
Publicado: (2023)

Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patients
por: Kusejko, Katharina, et al.
Publicado: (2022)

High Efficacy of Saliva in Detecting SARS-CoV-2 by RT-PCR in Adults and Children
por: Huber, Michael, et al.
Publicado: (2021)

Do we cause false positives? An experimental series on droplet or airborne SARS-CoV-2 contamination of sampling tubes during swab collection in a test center
por: Scheier, Thomas, et al.
Publicado: (2021)

Reduced Relative Sensitivity of the Elecsys SARS-CoV-2 Antigen Assay in Saliva Compared to Nasopharyngeal Swabs
por: Audigé, Annette, et al.
Publicado: (2021)

Cell-Cell Transmission Enables HIV-1 to Evade Inhibition by Potent CD4bs Directed Antibodies
por: Abela, Irene A., et al.
Publicado: (2012)

OMIP‐047: High‐Dimensional phenotypic characterization of B cells
por: Liechti, Thomas, et al.
Publicado: (2018)

Seroprofiling of Antibodies Against Endemic Human Coronaviruses and Severe Acute Respiratory Syndrome Coronavirus 2 in a Human Immunodeficiency Virus Cohort in Lesotho: Correlates of Antibody Response and Seropositivity
por: Brown, Jennifer A, et al.
Publicado: (2023)

Prominent bronchial vasculature, hemoptysis, and bilateral ground-glass opacities in a young woman with mitral stenosis
por: Aigner, Fabian, et al.
Publicado: (2016)

Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain’s exceptional capacity for sequence variation
por: Brandenberg, Oliver F, et al.
Publicado: (2014)

Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response
por: Marconato, Maddalena, et al.
Publicado: (2022)

Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States
por: Mues, Katherine E., et al.
Publicado: (2022)

Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework
por: Wang, Xuan, et al.
Publicado: (2023)

Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters
por: Brandenberg, Oliver F., et al.
Publicado: (2017)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland
por: Thoueille, Paul, et al.
Publicado: (2022)

Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies
por: Rusert, Peter, et al.
Publicado: (2011)

MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1
por: Ruprecht, Claudia R., et al.
Publicado: (2011)

Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy
por: Surial, Bernard, et al.
Publicado: (2023)

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
por: Haggenburg, Sabine, et al.
Publicado: (2022)

Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study
por: Hauser, Anthony, et al.
Publicado: (2020)

High-Throughput Sequencing of Human Immunoglobulin Variable Regions with Subtype Identification
por: Schanz, Merle, et al.
Publicado: (2014)

mrna-1273: Haematuria: 2 case reports
Publicado: (2021)

Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells
por: Liechti, Thomas, et al.
Publicado: (2019)

Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
por: Dickerman, Barbra A., et al.
Publicado: (2021)

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
por: Thompson, Mark G., et al.
Publicado: (2021)

Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation
por: Huang, Alice, et al.
Publicado: (2022)

Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study
por: Kusejko, Katharina, et al.
Publicado: (2018)

HIV-1 replication activates CD4(+) T cells with specificities for persistent herpes viruses
por: Haas, Anna, et al.
Publicado: (2010)

An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters
por: Salazar-Vizcaya, Luisa, et al.
Publicado: (2022)

BNT162b2, mRNA-1273, et EMA : une procédure qui roule
por: Dalmat, Yann-Mickael
Publicado: (2021)

The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273
por: Markewitz, Robert, et al.
Publicado: (2022)

Reply to correspondence ‘Conserved signatures indicate HIV-1 transmission is under strong selection and thus is not a “stochastic” process’ by Gonzalez et al., Retrovirology 2017
por: Oberle, Corinna S., et al.
Publicado: (2017)

Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
por: Puranik, Arjun, et al.
Publicado: (2022)

Multifactorial seroprofiling dissects the contribution of pre-existing human coronaviruses responses to SARS-CoV-2 immunity
por: Abela, Irene A., et al.
Publicado: (2021)

Migrating a Well-Established Longitudinal Cohort Database From Oracle SQL to Research Electronic Data Entry (REDCap): Data Management Research and Design Study
por: Kusejko, Katharina, et al.
Publicado: (2023)

The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis
por: Marzel, Alex, et al.
Publicado: (2018)

Serological response after COVID-19 mRNA-1273 booster dose in immunocompromised patients, Taiwan, July to August 2021
por: Lin, Kuan-Yin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oft2ju60odrqnhkkonc4uqv3d9